A phase 2, double-blind, randomized, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of three doses of TAK-128 in subjects with mild to moderate diabetic peripheral neuropathy.
Phase of Trial: Phase II
Latest Information Update: 09 Jun 2013
At a glance
- Drugs TAK 128 (Primary)
- Indications Diabetic neuropathies
- Focus Therapeutic Use
- Sponsors Takeda Global Research and Development Center
- 18 Dec 2008 Takeda Global Research & Development Center added as trial sponsor and affiliate as reported by Clinicaltrials.gov.
- 11 Sep 2008 Actual patient number (343) added as reported by ClinicalTrials.gov.
- 11 Sep 2008 Actual end date changed from 1 Feb 2007 to 1 May 2006 as reported by Clinicaltrials.gov